Therefore, findings from this study could provide more precise and reliable comprehensive assessment than those published meta-analyses on the predictive role of XRCC1 genetic polymorphisms in clinical outcomes of platinum-based chemotherapy treatment for advanced lung cancer patients. The gene discussed is XRCC1; the disease is lung carcinoma.